---
title: "CapsoVision 10-K: Revenue $13.6M, EPS $(1.03) — Annual Results"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280688218.md"
description: "CapsoVision reported fiscal-year revenue of $13.554 million, a 15% increase year-over-year, with a net loss per share of $(1.03). The company faced wider operating losses due to increased R&D and administrative spending, resulting in a net loss of $(25.315) million. Concerns about cash runway and financing plans were disclosed as the company seeks equity and private financings to support commercialization. Key growth drivers included a rise in CapsoCam Plus unit sales and expansion of U.S. direct sales."
datetime: "2026-03-26T20:55:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280688218.md)
  - [en](https://longbridge.com/en/news/280688218.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280688218.md)
---

# CapsoVision 10-K: Revenue $13.6M, EPS $(1.03) — Annual Results

CapsoVision reported fiscal-year revenue of $13.554 million and a net loss per share of $(1.03), reflecting higher unit sales alongside significant operating investments. Revenue rose 15% year‑over‑year driven by CapsoCam Plus unit sales, while operating losses widened due to increased R&D and general and administrative spending. The company reported a net loss and comprehensive loss of $(25.315) million and disclosed concerns about cash runway and financing plans to support commercialization.

**Financial Highlights**

-   **Revenue**: $13.554 million, up $1.798 million (15%) versus prior year.
-   **Gross Profit**: $7.173 million, up $0.796 million (12%); gross margin 53% (down 1 percentage point attributed to higher customs/tariffs).
-   **Operating Loss**: $(25.516) million, increased $(5.599) million (28%) versus prior year.
-   **Net loss and comprehensive loss**: $(25.315) million, increased $(5.417) million (27%) versus prior year.
-   **Net loss per share – basic and diluted**: $(1.03), compared with $(9.85) in the prior year (weighted‑average shares increased materially after IPO).

**Business Highlights**

-   **Revenue growth drivers**: 15% increase in CapsoCam Plus unit sales drove the rise in revenue.
-   **Channel and product mix**: Expansion of U.S. direct sales produced 17% U.S. growth and an increasing mix from CapsoCloud SaaS and reading services.
-   **R&D and clinical programs**: Continued heavy investment in the CapsoCam Colon pivotal study (second arm with more than 500 of 800 target enrolled) and submission of a 510(k) for an AI‑enabled CapsoCam Plus.
-   **Manufacturing and supply chain**: Capsules continue to be manufactured in‑house with critical components sourced from suppliers in Taiwan and Japan; development collaboration noted with Canon for CMOS technology.
-   **Operational runway and financing**: Elevated operating losses and cash burn raised going‑concern doubt; the company is pursuing equity and private financings to fund commercialization and ongoing operations.

Original SEC Filing: CapsoVision, Inc \[ CV \] - 10-K - Mar. 26, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CV.US](https://longbridge.com/en/quote/CV.US.md)

## Related News & Research

- [CapsoVision Reports First Quarter 2026 Financial Results | CV Stock News](https://longbridge.com/en/news/286459538.md)
- [OPENAI: OPENAI IS COLLABORATING WITH AI LEAP, THE UNIVERSITY OF TARTU, AND STANFORD](https://longbridge.com/en/news/287035011.md)
- [AI face is taking over — and driving plastic surgeons crazy](https://longbridge.com/en/news/286641783.md)
- [How Beaten-Down Tempus AI Stock Offers a Lottery Ticket for Traders Here](https://longbridge.com/en/news/286786866.md)
- [Jack Antonoff tells people who are making AI art to 'drive right off that cliff'](https://longbridge.com/en/news/286592426.md)